论文部分内容阅读
目的观察干扰素β-1b(IFNβ-1b)治疗复发缓解型多发性硬化(MS)患者的疗效并进行生活质量评估,进一步探索生活质量的相关因素。方法选择接受IFNB-1b治疗的MS患者13例,并于治疗后第1个月、3个月、6个月、9个月、12个月对患者进行随访,评估包括扩展的功能缺损状况(EDSS)评分、多发性硬化患者生活质量量表(MSQOL-54)及汉密尔顿焦虑抑郁量表(HAMA、HAMD)评分。结果经IFNB1b治疗的MS患者在第1、3、6、9、12个月随访时生活质量、EDSS、HAMA、HAMD评分与治疗前比较均无明显变化(P>0.05)。治疗前生活质量中躯体功能、性功能及对性生活满意度与EDSS评分呈负相关(P值均<0.05);情绪致角色受限、疼痛与病程呈正相关(P值均<0.05);躯体功能、情绪状况、社会功能、性功能及对性生活满意度与HAMA评分呈负相关(P值均<0.05);认知、应激与HAMD评分均呈负相关(P值均<0.05)。躯体致角色受限、精力、健康认知、总体生活质量及健康变化与病程、EDSS、HAMA、HAMD各项无相关性,年龄与MSQOL-54无关(P值均>0.05)。结论 IFNB-1b短期内可能对MS患者生活质量无明显影响,生活质量与患者的EDSS评分、焦虑抑郁症状相关。
Objective To observe the effects of interferon β-1b (IFNβ-1b) on patients with relapsing-remitting multiple sclerosis (MS) and assess the quality of life to further explore the related factors of quality of life. Methods Thirteen patients with MS treated with IFNB-1b were enrolled in this study. Patients were followed up 1 month, 3 months, 6 months, 9 months and 12 months after treatment to evaluate the effects of IFNB-1b on patients with extended functional impairment ( EDSS score, MSQOL-54 and HAMA score. Results The quality of life, EDSS, HAMA and HAMD scores of MS patients treated with IFNB1b at the 1st, 3rd, 6th, 9th and 12th months were not significantly different from those before treatment (P> 0.05). Body quality, sexual function and satisfaction with sex life were negatively correlated with EDSS scores before treatment (all P <0.05). The role of emotion was limited and the pain was positively correlated with the course of disease (P <0.05) There was a negative correlation between function, emotional status, social function, sexual function, and sexual satisfaction with HAMA score (P <0.05). There was a negative correlation between cognitive and stress scores and HAMD score (P <0.05). There were no correlations between body-induced role limitation, energy, health cognition, overall quality of life and health changes and duration of disease, EDSS, HAMA, HAMD, and age without MSQOL-54 (P> 0.05). Conclusion IFNB-1b may have no significant effect on quality of life in patients with MS in short term. Quality of life is related to EDSS score and symptoms of anxiety and depression in patients.